BrainScope Company, Inc. is a medical neuro-technology company that is pioneering the future of traumatic brain injury (TBI) assessment. The BrainScope® One device, utilizing Electroencephalogram (EEG) technology cleared by the FDA, is the first objective, adjunctive device capable of assessing the full spectrum of mild traumatic brain injury (mTBI/concussion). Its ability to rapidly identify the likelihood of both structural brain injury and functional brain impairment at the point of care offers an opportunity for dramatic improvement to the current treatment path for evaluating mTBI/concussion patients. The benefits could include diversion from the emergency department (ED), a major reduction in unnecessary CT scans, and early intervention for patients with functional injuries, including concussion—contributing to the best possible outcomes in the shortest possible time.
Results from clinical studies utilizing BrainScope’s technology have been independently published through 24 articles in leading peer-reviewed neurotrauma and emergency medicine journals.
BrainScope has been awarded more than $32 million of U.S. Department of Defense research contracts for the development of its TBI and concussion assessment technology and has received two awards from GE and the NFL through its Head Health Challenge I. The company has received significant funding from private investors including Revolution (created by AOL co-founder Steve Case), State of Maryland Venture Fund, ZG Ventures, Brain Trust Accelerator Fund, Difference Capital and DBL Partners.
BrainScope holds over 100 issued and pending global patents.